Zoetis Inc. (NYSE:ZTS) Stake Trimmed by American National Bank & Trust

American National Bank & Trust lowered its stake in Zoetis Inc. (NYSE:ZTS) by 7.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,023 shares of the company’s stock after selling 166 shares during the quarter. American National Bank & Trust’s holdings in Zoetis were worth $333,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Atlantic Edge Private Wealth Management LLC grew its stake in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares in the last quarter. Rakuten Securities Inc. grew its stake in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares in the last quarter. Navigoe LLC purchased a new position in Zoetis during the 4th quarter valued at about $30,000. Murphy & Mullick Capital Management Corp purchased a new position in Zoetis during the 4th quarter valued at about $44,000. Finally, Asset Planning Inc purchased a new position in Zoetis during the 4th quarter valued at about $58,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Stifel Nicolaus reduced their price target on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. Finally, Piper Sandler lifted their price target on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $212.75.

Zoetis Stock Up 0.9%

Shares of ZTS stock opened at $168.71 on Monday. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The firm has a market cap of $75.11 billion, a PE ratio of 30.84, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The stock has a 50 day moving average of $156.80 and a 200-day moving average of $164.43. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis’s revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share. On average, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.19%. Zoetis’s payout ratio is 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.